Why Analysts Believe RAC is “Highly Undervalued”, page-119

It's not a new drug; it's a new formulation with long lasting IP protection. Not only are there short cuts; they're actually legitimate pathways and we have a map; and the team have access to a secret passage that was revealed during the manufacturing delays.

You down-ramping butt heads with your BS nonsense clichés: "don't put the cart before the horse". That's a straw man argument, where the cart and horse* are an inaccurate analogy, making your argument not just weak but actually invalid - you have the brain of an Ape (as mentioned before, we all do; it's just worth recognising that fact and then training yourself to try to avoid the pitfalls).

A bloody strategy is a plan where you identify a target that is the best thing you can aim for when you've weighed up your assets, your capabilities and your chances of success; you put together a roadmap that's flexible to when you learn new things going forward; and then you pursue it with intent. You have to have a goal to aim for. It's not putting the cart before the horse, it's having some knowledge, some ambition, some integrity and a lot of grit and determination.


*Note: The "Horse before the Cart" saying is an analogy for doing things in the wrong order. Identifying the need for a new formulation that has 100's of times more applications; successfully manufacturing that formulation and then carefully crafting a strategy to bring it through the clinic to market in a way that maximises returns for shareholders and gets it to patients, is doing things in the right order; and it's doing it successfully.